Maribavir (ViroPharma).
Copyright policy )Maribavir (ViroPharma).
ViroPharma, under license from GlaxoSmithKline, is developing maribavir, a DNA synthesis inhibitor for the potential prevention and treatment of human cytomegalovirus infections related to transplants (including solid organ and hematopoietic stem cells), congenital transmission, and in patients with HIV infection. In July 2004, a phase II trial was initiated.
Clinical Trials, Phase I as Topic, Antiviral Agents, Patents as Topic, Structure-Activity Relationship, Clinical Trials, Phase II as Topic, Cytomegalovirus Infections, Animals, Humans, Benzimidazoles, Ribonucleosides, Dichlororibofuranosylbenzimidazole, Nucleic Acid Synthesis Inhibitors, Randomized Controlled Trials as Topic
Clinical Trials, Phase I as Topic, Antiviral Agents, Patents as Topic, Structure-Activity Relationship, Clinical Trials, Phase II as Topic, Cytomegalovirus Infections, Animals, Humans, Benzimidazoles, Ribonucleosides, Dichlororibofuranosylbenzimidazole, Nucleic Acid Synthesis Inhibitors, Randomized Controlled Trials as Topic
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).16 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!